Stem cell collection with motixafortide and G-CSF for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, motixafortide, combined with a standard growth factor (G-CSF) to help collect stem cells for a transplant in people with multiple myeloma. It may be a good option if your myeloma is in remission and you have not had a stem cell transplant before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 78 years old.
- You have active multiple myeloma and are in your first or second remission (complete or partial response).
- You have not had a stem cell transplant before and have not failed a previous stem cell collection.
- You are in good overall health (ECOG score of 0 or 1) and your organs are working well enough for the procedure.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use effective birth control.
- You have not taken certain medications (like lenalidomide, bortezomib, or G-CSF) within the required washout period (usually 7 to 42 days depending on the drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
This trial tests two different steroid medicines (methylprednisolone and dexamethasone) to see which works better at preventing side effects from motixafortide, a drug used to help collect stem cells for a stem cell transplant in people with multiple myeloma.
This study tests if adding Mozobil (a drug that helps release stem cells) before stem cell transplant can improve outcomes for people with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin lymphoma. If you are eligible, you will receive Mozobil along with standard stem cell mobilization medicines.
This study tests two different combinations of medicines to help collect stem cells for a transplant in people newly diagnosed with multiple myeloma. The goal is to see which approach works better and is safer for you.
This study tests a combination of four cancer-fighting drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) followed by a stem cell transplant for people newly diagnosed with multiple myeloma. The goal is to see if this approach can help patients live longer and control their disease better.
This trial tests a specific chemotherapy combination (thiotepa and melphalan) given before a stem cell transplant to treat multiple myeloma. The study compares this approach to help doctors understand if it improves outcomes for patients whose myeloma hasn't fully responded to initial treatment.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.